Parexel Expands Model-Based Drug Development Offering

Applied Clinical Trials

Parexel announced expanded services and capabilities in model-based drug development (MBDD) through its Quantitative Clinical Development (QCD) group.

 

Parexel announced expanded services and capabilities in model-based drug development (MBDD) through its Quantitative Clinical Development (QCD) group.  The Parexel QCD leverages mathematical models for a quantitative analysis of the relationship between drugs, disease and patients, modeling and simulation can predict a drug’s benefits and adverse effects in a patient population prior to conducting a clinical trial. MBDD can improve the efficiency of clinical development by providing quantitative justification for trial design, dose selection, and decisions during trial execution.